Related references
Note: Only part of the references are listed.Graft-versus-host disease risk after chimeric antigen receptor T-cell therapy: the diametric opposition of T cells
Khaled Sanber et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Chimeric antigen receptor T-cell therapy after allogeneic stem cell transplant for relapsed/refractory large B-cell lymphoma
Forat Lutfi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
Maria-Luisa Schubert et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Efficacy and safety of anti-CD19 CAR T-cell therapy in 110 patients with B-cell acute lymphoblastic leukemia with high-risk features
Xian Zhang et al.
BLOOD ADVANCES (2020)
Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant
Pengjiang Liu et al.
FRONTIERS IN ONCOLOGY (2020)
Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma
Marcelo C. Pasquini et al.
BLOOD ADVANCES (2020)
Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/refractory B cell non-Hodgkin lymphoma
Tania Jain et al.
LEUKEMIA (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL
Kevin J. Curran et al.
BLOOD (2019)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
Karen Thudium Mueller et al.
BLOOD (2017)
Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation
Yuhong Chen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Share Paper
